Rhythm Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Rhythm Pharmaceuticals Inc 公司

Rhythm Pharmaceuticals, Inc. 是一家商業階段的生物製藥公司。該公司專注於推進其黑皮質素-4 受體 (MC4R) 激動劑，包括其主要資產 IMCIVREE，這是一種精準醫療，旨在治療由罕見的 MC4R 通路疾病引起的暴食症和嚴重肥胖症。IMCIVREE 已獲得美國食品藥品管理局 (FDA) 批准，用於治療因阿片黑皮質素原 (POMC)、前蛋白轉化酶枯草溶菌素/kexin 1 型 (PCSK1) 或瘦素受體 (LEPR) 缺乏而導致的單基因或綜合徵性肥胖的成人和 6 歲及以上的兒童患者的慢性體重管理，經 FDA 批准的測試確定，POMC、PCSK1 或 LEPR 基因中的變異被解釋爲致病、可能致病或意義不明 (VUS)；或 Bardet-Biedl 綜合徵 (BBS)。該公司正在 II 期和 III 期試驗中評估 setmelanotide 對治療因與 MC4R 通路相關的衆多基因之一變異而導致的肥胖症的效果。

公司簡介

公司代碼RYTM

公司名稱Rhythm Pharmaceuticals Inc

上市日期Oct 05, 2017

成立日期2013

CEO- -

員工數量283

證券類型Ordinary Share

年結日Oct 05

公司地址222 Berkeley Street

城市BOSTON

上市交易所NASDAQ Global Market Consolidated

國家United States of America

郵編02116

電話18572644280

網址https://rhythmtx.com/

公司代碼RYTM

上市日期Oct 05, 2017

成立日期2013

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. David P. Meeker ,M.D.

Chairman of the Board, President, Chief Executive Officer

201.82K

--

Mr. Hunter C. Smith

Chief Financial Officer, Treasurer

116.92K

+6.36%

Mr. Yann Mazabraud

Executive Vice President, Head of International

37.66K

-6.73%

Mr. Joseph (Joe) Shulman

Chief Technical Officer

8.51K

-0.35%

Ms. Jennifer L. Good

Independent Director

7.00K

+133.33%

Mr. Christophe R. Jean

Independent Director

7.00K

+133.33%

Dr. Camille L. Bedrosian, M.D.

Independent Director

7.00K

+133.33%

Mr. Stuart A. Arbuckle

Independent Director

7.00K

+133.33%

Ms. Lynn A. Tetrault, J.D.

Independent Director

--

Dr. Alastair (Al) Garfield, Ph.D.

Chief Scientific Officer

--

名稱

名稱/職務

職務

持股

持股變動

Dr. David P. Meeker ,M.D.

Chairman of the Board, President, Chief Executive Officer

201.82K

--

Mr. Hunter C. Smith

Chief Financial Officer, Treasurer

116.92K

+6.36%

Mr. Yann Mazabraud

Executive Vice President, Head of International

37.66K

-6.73%

Mr. Joseph (Joe) Shulman

Chief Technical Officer

8.51K

-0.35%

Ms. Jennifer L. Good

Independent Director

7.00K

+133.33%

Mr. Christophe R. Jean

Independent Director

7.00K

+133.33%

收入明細

單位: USD更新時間: 7月6日週日

FY2024

FY2023

FY2022

FY2021

暫無數據

地區USD

名稱

營收

佔比

United States

96.11M

73.86%

International

34.02M

26.14%

業務

地區

暫無數據

股東統計

更新時間: 5月17日週六

持股股東

股東類型

持股股東

佔比

RA Capital Management, LP

9.56%

PRIMECAP Management Company

9.10%

Baker Bros. Advisors LP

8.81%

BlackRock Institutional Trust Company, N.A.

6.29%

The Vanguard Group, Inc.

5.40%

Other

60.85%

持股股東

佔比

RA Capital Management, LP

9.56%

PRIMECAP Management Company

9.10%

Baker Bros. Advisors LP

8.81%

BlackRock Institutional Trust Company, N.A.

6.29%

The Vanguard Group, Inc.

5.40%

Other

60.85%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

33.95%

Investment Advisor

29.07%

Venture Capital

15.18%

Hedge Fund

14.38%

Private Equity

5.67%

Research Firm

3.79%

Individual Investor

0.70%

Bank and Trust

0.70%

Sovereign Wealth Fund

0.32%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

446

66.23M

104.10%

-6.62M

2025Q1

464

66.24M

104.13%

-6.91M

2024Q4

438

66.17M

104.69%

-7.75M

2024Q3

414

68.98M

112.28%

-7.86M

2024Q2

402

70.62M

115.59%

-5.66M

2024Q1

385

68.75M

112.78%

-8.84M

2023Q4

369

67.33M

113.30%

-8.52M

2023Q3

350

68.72M

116.31%

-2.96M

2023Q2

327

67.69M

118.97%

+564.21K

2023Q1

340

61.98M

109.09%

-8.65M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

RA Capital Management, LP

6.08M

9.56%

--

Mar 31, 2025

PRIMECAP Management Company

5.79M

9.1%

-783.87K

-11.93%

Mar 31, 2025

Baker Bros. Advisors LP

5.60M

8.81%

-479.77K

-7.89%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.00M

6.29%

-64.82K

-1.59%

Mar 31, 2025

The Vanguard Group, Inc.

3.43M

5.4%

+2.33K

+0.07%

Mar 31, 2025

New Enterprise Associates (NEA)

2.91M

4.57%

--

Mar 31, 2025

Perceptive Advisors LLC

2.55M

4.01%

-1.13M

-30.76%

Mar 31, 2025

State Street Global Advisors (US)

1.97M

3.1%

+129.86K

+7.05%

Mar 31, 2025

BlackRock Financial Management, Inc.

1.69M

2.66%

-26.51K

-1.54%

Mar 31, 2025

Janus Henderson Investors

1.66M

2.6%

+435.80K

+35.73%

Mar 31, 2025

持股ETF

更新時間: 7月6日週日

機構名稱

佔比

ALPS Medical Breakthroughs ETF

3.41%

Virtus LifeSci Biotech Products ETF

1.99%

Innovator IBD 50 Fund ETF

1.93%

Harbor Health Care ETF

1.69%

Harbor Human Capital Factor US Small Cap ETF

1.42%

iShares Health Innovation Active ETF

1.19%

SPDR S&P Biotech ETF

0.86%

Federated Hermes MDT Small Cap Core ETF

0.7%

NYLI Healthy Hearts ETF

0.61%

First Trust Small Cap Growth AlphaDEX Fund

0.56%

ALPS Medical Breakthroughs ETF

佔比3.41%

Virtus LifeSci Biotech Products ETF

佔比1.99%

Innovator IBD 50 Fund ETF

佔比1.93%

Harbor Health Care ETF

佔比1.69%

Harbor Human Capital Factor US Small Cap ETF

佔比1.42%

iShares Health Innovation Active ETF

佔比1.19%

SPDR S&P Biotech ETF

佔比0.86%

Federated Hermes MDT Small Cap Core ETF

佔比0.7%

NYLI Healthy Hearts ETF

佔比0.61%

First Trust Small Cap Growth AlphaDEX Fund

佔比0.56%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Rhythm Pharmaceuticals Inc

89.040USD

Rhythm Pharmaceuticals Inc

89.040

概覽

公司

財務